Published in Clin Cancer Res on August 01, 1997
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med (2010) 6.34
Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients. J Clin Oncol (2004) 2.16
A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group. Clin Cancer Res (2006) 1.91
Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study. J Clin Oncol (2010) 1.57
Anti-GD2 antibody therapy for GD2-expressing tumors. Curr Cancer Drug Targets (2010) 1.28
Combination strategies to enhance antitumor ADCC. Immunotherapy (2012) 1.12
Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma. J Clin Oncol (2014) 1.09
Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma. Cancer (2013) 1.02
The development of antibody-IL-2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastoma. Expert Opin Investig Drugs (2009) 0.92
Peptides mimicking GD2 ganglioside elicit cellular, humoral and tumor-protective immune responses in mice. Cancer Immunol Immunother (2008) 0.87
Current and Potential Uses of Immunocytokines as Cancer Immunotherapy. Antibodies (Basel) (2012) 0.86
GD2-targeted immunotherapy and radioimmunotherapy. Semin Oncol (2014) 0.86
Immune therapies for neuroblastoma. Cancer Biol Ther (2009) 0.85
Antibody-cytokine fusion proteins: applications in cancer therapy. Expert Opin Biol Ther (2008) 0.84
Spinal injection of IL-2 or IL-15 alters mechanical and thermal withdrawal thresholds in rats. Neurosci Lett (2008) 0.81
Enhancing Cancer Immunotherapy Via Activation of Innate Immunity. Semin Oncol (2015) 0.79
Anti-GD2 mAbs and next-generation mAb-based agents for cancer therapy. Immunotherapy (2016) 0.77
Posterior reversible encephalopathy syndrome in neuroblastoma patients receiving anti-GD2 3F8 monoclonal antibody. Cancer (2013) 0.77
Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell (1994) 9.51
A procedure for rapid and sensitive staining of protein fractionated by polyacrylamide gel electrophoresis. Anal Biochem (1967) 7.96
Graft-versus-leukemia reactions after bone marrow transplantation. Blood (1990) 7.11
Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med (2001) 5.59
Generation of protein-reactive antibodies by short peptides is an event of high frequency: implications for the structural basis of immune recognition. Proc Natl Acad Sci U S A (1983) 4.56
Protein iodination with solid state lactoperoxidase. Biochemistry (1974) 4.52
Major-histocompatibility-complex class I alleles and antigens in hematopoietic-cell transplantation. N Engl J Med (2001) 3.98
Electrophoretic heterogeneity of polypeptide chains of specific antibodies. Science (1966) 3.88
Differential function of major histocompatibility complex antigens in T-lymphocyte activation. Nature (1976) 3.87
Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol (1999) 3.48
Enhancement of sheep red blood cell human lymphocyte rosette formation by the sulfhydryl compound 2-amino ethylisothiouronium bromide. Clin Immunol Immunopathol (1975) 3.11
Cell mediated immunity: separation of cells involved in recognitive and destructive phases. Science (1973) 3.04
Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol (1997) 2.79
Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer (2005) 2.71
Integrin alpha v beta 3 rescues melanoma cells from apoptosis in three-dimensional dermal collagen. Proc Natl Acad Sci U S A (1994) 2.30
Cytoplasmic localization of human cdc25C during interphase requires an intact 14-3-3 binding site. Mol Cell Biol (1999) 2.21
Unique glycoprotein-proteoglycan complex defined by monoclonal antibody on human melanoma cells. Proc Natl Acad Sci U S A (1982) 2.21
Salt extraction of soluble HL-A antigens. Science (1971) 2.18
Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia. Biol Blood Marrow Transplant (2001) 2.10
Separation of 7S gamma-1-globulin, 7S gamma-2-globulin and macroglobulin guinea pig antibodies. Proc Soc Exp Biol Med (1966) 2.08
Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. Proc Natl Acad Sci U S A (1992) 2.07
Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood (2001) 2.04
Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. Cancer Res (1984) 2.01
Serologic evidence for antigens controlled by the Ir region in mice. J Exp Med (1973) 1.94
Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia (2006) 1.92
HL-A LD (lymphocyte defined) typing: a rapid assay with primed lymphocytes. Science (1975) 1.91
Endovascular treatment of acute carotid blow-out syndrome. J Vasc Interv Radiol (2000) 1.85
Immunologic functions of isolated human lymphocyte subpopulations. III. Specific allogeneic lympholysis mediated by human T cells alone. J Immunol (1975) 1.83
Antigenic requirements for triggering of cytotoxic T lymphocytes. Immunol Rev (1977) 1.82
Defective ubiquitinylation of EGFR mutants of lung cancer confers prolonged signaling. Oncogene (2007) 1.79
Structural studies of murine I-E and human DR antigens. Mol Immunol (1979) 1.79
Transplantation antigens. Adv Immunol (1970) 1.70
Murine Ia and human DR antigens: homology of amino-terminal sequences. Proc Natl Acad Sci U S A (1978) 1.70
Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2. Cancer Res (1990) 1.69
Downregulation of transcription factor SOX2 in cancer stem cells suppresses growth and metastasis of lung cancer. Br J Cancer (2011) 1.69
Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth. Cancer Res (1987) 1.68
Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer. J Clin Oncol (1994) 1.67
Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. J Clin Oncol (1998) 1.67
Biologic-response-modifier-induced indoleamine 2,3-dioxygenase activity in human peripheral blood mononuclear cell cultures. J Immunol (1987) 1.65
Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood (1997) 1.64
Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow. J Natl Cancer Inst (1997) 1.64
Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy. Blood (1998) 1.64
A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group. Cancer (1997) 1.63
A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma. Eur J Cancer (1995) 1.59
A rapid method for direct HL-A typing of cultured lymphoid cells. J Immunol (1971) 1.55
A phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer. Clin Cancer Res (2000) 1.55
Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells. Proc Natl Acad Sci U S A (1992) 1.51
Characterization of Ia antigens in mouse serum. J Immunol (1976) 1.51
Severe combined immunodeficiency, interleukin-2 (IL-2), and the IL-2 receptor: experiments of nature continue to point the way. Blood (1994) 1.50
TCGF production for cloning and growth of functional human T lymphocytes. Scand J Immunol (1980) 1.50
Human neural cell adhesion molecule L1 and rat homologue NILE are ligands for integrin alpha v beta 3. J Cell Biol (1996) 1.50
Gamma/delta T cell clones and natural killer cell clones mediate distinct patterns of non-major histocompatibility complex-restricted cytolysis. J Exp Med (1990) 1.50
Effect of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells. Cancer Res (1991) 1.48
Antigens associated with a human lung adenocarcinoma defined by monoclonal antibodies. Cancer Res (1984) 1.48
Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18. Cancer Res (1989) 1.45
An Arg-Gly-Asp-directed receptor on the surface of human melanoma cells exists in an divalent cation-dependent functional complex with the disialoganglioside GD2. J Cell Biol (1987) 1.44
Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody. J Immunol (1990) 1.44
A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14.G2a. Cancer Immunol Immunother (1992) 1.44
Treatment of hypercalcemia of malignancy with intravenous etidronate. A controlled, multicenter study. The Hypercalcemia Study Group. Arch Intern Med (1991) 1.43
Production and characterization of monoclonal antibody to a melanoma specific glycoprotein. Hybridoma (1981) 1.42
Interferon-induced indoleamine 2,3-dioxygenase activity in human mononuclear phagocytes. J Leukoc Biol (1989) 1.41
Prospects for clinical cancer treatment using interleukin-2. Cancer Invest (1989) 1.39
Localization of the gangliosides GD2 and GD3 in adhesion plaques and on the surface of human melanoma cells. Proc Natl Acad Sci U S A (1984) 1.39
O-acetylation of disialoganglioside GD3 by human melanoma cells creates a unique antigenic determinant. Science (1984) 1.38
Effect of tissue inhibitor of the matrix metalloproteinases-2 expression on the growth and spontaneous metastasis of a human melanoma cell line. Cancer Res (1994) 1.36
Identification of a direct interaction between interleukin 2 and the p64 interleukin 2 receptor gamma chain. Proc Natl Acad Sci U S A (1993) 1.35
Cells degrade a novel inhibitor of differentiation with E1A-like properties upon exiting the cell cycle. Mol Cell Biol (2000) 1.35
Impact of fumigants on soil microbial communities. Appl Environ Microbiol (2001) 1.33
Remodeling of collagen matrix by human tumor cells requires activation and cell surface association of matrix metalloproteinase-2. Cancer Res (1998) 1.33
Isolation and characterization of a mitogen from pokeweek (Phytolacca americana). Proc Natl Acad Sci U S A (1967) 1.32
Matrix metalloproteinase-2 activation modulates glioma cell migration. J Cell Sci (1997) 1.31
Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small-cell lung cancer. J Clin Oncol (1996) 1.31
A monoclonal antibody recognizes an O-acylated sialic acid in a human melanoma-associated ganglioside. J Biol Chem (1984) 1.31
Lymphokine-activated killer activity induced by in vivo interleukin 2 therapy: predominant role for lymphocytes with increased expression of CD2 and leu19 antigens but negative expression of CD16 antigens. Cancer Res (1989) 1.29
Chronic kidney disease following non-myeloablative hematopoietic cell transplantation. Am J Transplant (2006) 1.29
Proteases and protease inhibitors in tumor progression. Adv Exp Med Biol (1997) 1.27
KSA antigen Ep-CAM mediates cell-cell adhesion of pancreatic epithelial cells: morphoregulatory roles in pancreatic islet development. J Cell Biol (1998) 1.26
Long-term growth of lymphokine-activated killer (LAK) cells: role of anti-CD3, beta-IL 1, interferon-gamma and -beta. J Immunol (1987) 1.26
Targeting of lymphotoxin-alpha to the tumor elicits an efficient immune response associated with induction of peripheral lymphoid-like tissue. Immunity (2001) 1.26
Molecular cloning of a human melanoma-associated chondroitin sulfate proteoglycan. Proc Natl Acad Sci U S A (1996) 1.25
Marrow transplants from unrelated donors for patients with aplastic anemia: minimum effective dose of total body irradiation. Biol Blood Marrow Transplant (2001) 1.25
Predicting gene promoter methylation in non-small-cell lung cancer by evaluating sputum and serum. Br J Cancer (2007) 1.24
Effectiveness of smoking cessation interventions integrated into primary care practice. Med Care (1988) 1.23
Gene gun-mediated skin transfection with interleukin 12 gene results in regression of established primary and metastatic murine tumors. Proc Natl Acad Sci U S A (1996) 1.23
Cell-mediated destruction of human leukemic cells by MHC identical lymphocytes: requirement for a proliferative trigger in vitro. J Immunol (1976) 1.22
Elimination of established murine colon carcinoma metastases by antibody-interleukin 2 fusion protein therapy. Cancer Res (1997) 1.22
Correlation of chondroitin sulfate proteoglycan expression on proliferating brain capillary endothelial cells with the malignant phenotype of astroglial cells. Cancer Res (1991) 1.22
Biosynthetic studies of proteoglycans in human melanoma cells with a monoclonal antibody to a core glycoprotein of chondroitin sulfate proteoglycans. J Biol Chem (1984) 1.22
Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancer. Cancer Res (1988) 1.22